Cancer-Associated Thrombosis: From Primary to Secondary Prophylaxis
Presentation by Dr Laura Kirui

Dr Laura Kirui delivered a focused clinical update on cancer-associated thrombosis (CAT), addressing its epidemiology, pathophysiology and evidence-based prevention and treatment strategies across the cancer care continuum.

The presentation highlighted the significantly increased risk of venous thromboembolism (VTE) among cancer patients and its associated morbidity and mortality. Mechanistic insights into cancer-driven hypercoagulability including inflammation, dysregulated fibrinolysis, and tumor host cellular interactions were reviewed to contextualize clinical risk.

Emphasis was placed on risk stratification, particularly the use of validated tools such as the Khorana score, to guide decisions on primary thromboprophylaxis. Data supporting the use of low molecular weight heparin and selected direct oral anticoagulants in high-risk populations were discussed, alongside bleeding considerations. The session also addressed therapeutic anticoagulation, duration of treatment, secondary prophylaxis and management in special scenarios including thrombocytopenia, catheter-related thrombosis and incidental VTE.

Key takeaway: Individualized risk assessment and ongoing reassessment are central to optimizing prevention and management of cancer-associated thrombosis.